HIV/AIDS
Sequoia Pharmaceuticals Files Second IND for 2007
Published in AIDS Weekly, December 24th, 2007
Sequoia Pharmaceuticals, Inc. announced that it has submitted an investigational New Drug Application (IND) with the United States Food and Drug Administration to begin human clinical trials with SPI-452, a novel pharmacokinetic enhancer. SPI-452 is designed to improve the exposure of co-administered HIV medications thereby providing more efficacious, less toxic and more user-friendly drug regimens.
Sequoia's first IND was submitted for its' novel HIV protease inhibitor, SPI-256, in February 2007, and ongoing Phase I clinical trials continue to yield favorable results.
"I am very impressed with the accomplishments of the teams at Sequoia. To have...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
Source: AIDS Weekly (2007-12-24)
More Articles from AIDS Weekly
- Cancer Vaccines
New study suggests why vaccines directed against cancer, HIV don't work - HIV/AIDS
Studies suggest HIV subtype more deadly than others - HIV/AIDS
Reports outline HIV/AIDS study findings from Khon Kaen University - HIV/AIDS Cancer
Research results from P.T. Pitche and co-authors update knowledge of HIV/AIDS cancer - HIV/AIDS Co-Infection
Findings from Y.H. Wang and co-researchers advance knowledge in HIV/AIDS co-infection - HIV/AIDS Co-Infection
Reports on HIV/AIDS co-infection findings from A. Mellgren and co-researchers provide new insights - More from this issue of AIDS Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
